›
^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersTEST:AmoyDx® BRCA Pro Panel
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Amoy DiagnosticsType:
Laboratory Developed Test
Related tests:
The AmoyDx® BRCA Pro Panel is a next-generation sequencing (NGS) based in vitro diagnostic assay intended for qualitative detection and classification of single nucleotide variants (SNVs), insertions and deletions (InDels), and large rearrangements (LRs) in protein coding regions, intron/exon boundaries, some introns and UTR regions of the BRCA1 and BRCA2 genes, using DNA isolated from peripheral whole blood or formalin-fixed paraffin embedded (FFPE) tumour tissue specimens. The detection of large rearrangement deletions and duplications is available for blood-derived DNA only. The assay is intended to aid in identifying breast cancer or ovarian cancer patients with pathogenic, or likely pathogenic BRCA variants.
Cancer:
Breast Cancer, Ovarian Cancer
Gene:
BRCA1 (Breast cancer 1, early onset), BRCA2 (Breast cancer 2, early onset)
BRCA1 (Breast cancer 1, early onset), BRCA2 (Breast cancer 2, early onset)
Method:
Next-Generation Sequencing (NGS)
